Vera-Aguilera J, et al. - Experts tested the premise that hepatic arterial infusion (HAI) of nab-paclitaxel would deliver an efficacious dose of drug to the end organ of interest, with minimal systemic exposure in patients with metastatic melanoma (MM) to the liver. A single-institution open-label phase I/II study of HAI of nab-paclitaxel was performed in 30 MM patients with liver metastasis. In melanoma patients with liver metastases, rare objective responses were seen with HAI nab-paclitaxel. In order to enhance meaningful responses, authors suggested evaluating this treatment in combination with checkpoint blockade or other novel treatments, but it should not be thought of as effective as monotherapy.